Subscriber access provided by Iowa State University | Library
Article 2
D-Enantiomeric RTHLVFFARK-NH: A Potent Multifunctional Decapeptide Inhibiting Cu -Mediated Amyloid #-Protein Aggregation and Remodeling Cu -Mediated Amyloid # Aggregates 2+
2+
Wei Liu, Xiaoyan Dong, and Yan Sun ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.8b00440 • Publication Date (Web): 16 Jan 2019 Downloaded from http://pubs.acs.org on January 18, 2019
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
D-Enantiomeric RTHLVFFARK-NH2: A Potent Multifunctional
2
Decapeptide
3
Aggregation and Remodeling Cu2+-Mediated Amyloid β Aggregates
Inhibiting
Cu2+-Mediated
Amyloid
β-Protein
4 5
Wei Liu, Xiaoyan Dong and Yan Sun*
6
Department of Biochemical Engineering and Key Laboratory of Systems
7
Bioengineering of the Ministry of Education, School of Chemical Engineering and
8
Technology, Tianjin University, Tianjin 300354, China
1
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
9
ABSTRACT:
10
Aggregation of amyloid β-protein (Aβ) into β-sheet-rich plaques is a general feature
11
of Alzheimer’s disease (AD). Homeostasis dysregulation of Cu2+ mediates Aβ to form
12
high cytotoxic aggregates, which causes cell damages by generation of reactive
13
oxygen species (ROS). To improve the inhibitory potency and explore the
14
multifaceted functions of our previously designed decapeptide, RTHLVFFARK-NH2
15
(RK10), we have herein reformulated the decapeptide into its D-enantiomer, rk10, and
16
the effects of chirality on Aβ aggregation, Cu2+-mediated Aβ aggregations and
17
aggregate-remodeling effects were investigated. The results revealed the following:
18
(1) The D-enantiomer presented enhanced inhibitory potency on Aβ fibrillogenesis in
19
comparison to RK10; rk10 and RK10 increased the cell viability from 60% to 91%
20
and 71%, respectively, at an equimolar concentration to Aβ. (2) The enantiomers were
21
chemically equivalent to Cu2+ chelation, ROS suppression and oxidative damage
22
rescue. (3) The D-enantiomer exhibited higher performance to inhibit Cu2+-mediated
23
Aβ aggregation, and more significantly attenuated the cytotoxicity caused by
24
Aβ42-Cu2+ complex than RK10. Cell viability was rescued from 51% to 89% and 74%
25
by co-incubating with rk10 and RK10 at 50 μM, respectively. Intracellular ROS levels
26
generated by Aβ42 and Aβ42-Cu2+ species were also remarkably decreased by treating
27
with rk10. (4) The enantiomers could remodel mature Aβ42-Cu2+ aggregates by Cu2+
28
chelation, and rk10 showed higher performance than RK10, as evidenced by the
29
enhanced cell viability from 57% to 86% by RK10 and to 96% by rk10. The
30
D-enantiomer also showed higher ability than RK10 on protecting the disrupted
31
species from reaggregation. Taken together, D-chiral derivatization of the decapeptide
32
resulted in a potent multifunctional agent in inhibiting Cu2+-mediated Aβ aggregation
33
and remodeling mature Aβ-Cu2+ species. To the best of our knowledge, this is the first
34
investigation on the chirality effect of a multifunctional peptide inhibitor on
35
Cu2+-mediated Aβ aggregation and on the remodeling effect of mature Aβ-Cu2+
36
aggregates. The work provided new insights into the critical role of chirality in the
37
multifaceted functions of peptide inhibitors against amyloid formation and its toxicity.
38 39
KEYWORDS: Alzheimer’s disease, amyloid β-protein, multifunctional inhibitor,
40
D-enantiomeric peptide, chirality, oxidative stress.
2
ACS Paragon Plus Environment
Page 2 of 38
Page 3 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
41
INTRODUCTION
42
Alzheimer’s disease is one of the most prevalent and devastating neurodegenerative
43
diseases with an increasing incidence in recent years.1-3 The histopathological
44
hallmarks of AD are extracellular amyloid plaques and intracellular neurofibrillary
45
tangles in patients’ hippocampus.4 Amyloid β-protein (Aβ), the main component of
46
senile plaques, is highly related to neurons disfunction and memory deficits.5,6 Aβ is a
47
hydrophobic, intrinsically disordered, and aggregation-prone peptide consisting of
48
39−43 amino acid residues.7 Elevated levels of Aβ drive its aggregation into soluble
49
oligomer, protofibrils and finally mature fibrils.4,6 The intermediates of aggregation
50
have been accepted as the most toxic species to neurons.2,8,9 Therefore, Aβ cascade
51
hypothesis strongly supports exploration of inhibitors that can suppress Aβ
52
aggregation and reduce its cytotoxicity for development of potential drug candidates
53
for the treatment of AD.3,10-12 Meanwhile, investigations have revealed that the
54
homeostasis dysregulation of transition metal ions, especially Cu2+, not only mediate
55
Aβ aggregation into high-cytotoxicity species, but also produce reactive oxygen
56
species (ROS) including oxygen-free radicals (HO•) and hydrogen peroxide (H2O2)
57
via Fenton-type reactions, which cause severe oxidative stress.11,13,14 Therefore,
58
various metal-ion chelators have been studied for AD treatment.13,15,16 Considering
59
the complexity of AD onset (Aβ aggregation, metal dyshomeostasis, oxidative stress,
60
inflammation, and so on), the concept of “multifunctional inhibitor” has emerged. A
61
multifunctional inhibitor should possess two or more functions, such as inhibition of
62
Aβ aggregation into toxic species and chelation of transition-metal ions to arrest its
63
activities on ROS production as well as on enhancing the amyloid toxicity.12,17-19
64
Over the past decade, vigorous progress has been made in the design and
65
development of Aβ inhibitors and multifunctional inhibitors. These include
66
peptides,15,18,20-24
67
antibodies,33 and proteins.19,34,35 Small peptide-based inhibitors have attracted
68
extensive attention due to their high target affinity, easy synthesis, and favorable
69
biocompatibility.20,24 A series of peptide-based inhibitors such as D3 (rprtrlhrnr) and
small
molecules,14,17,25,26
nanoparticles,27-30
3
ACS Paragon Plus Environment
polymers,31,32
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
70
its derivatives are identified to be promising inhibitors and have entered Phase I
71
clinical trials.36-40 Numerous peptides have been designed to target the hydrophobic
72
core of Aβ sequence (Aβ16-20) and yielded encouraging results,20 such as β-sheet
73
breaker LPFFD,41 LVFFARK (LK7),29,42 and RTHLVFFARK (RK10).18 However,
74
there are still increasing demands on potent (multifunctional) inhibitors that work at
75
low concentrations.20
76
Recent studies have demonstrated that the aggregation of natural Aβ is sensitive to
77
chiral environment.43,44 For example, addition of the mirror image D-Aβ42 to the
78
natural L-Aβ42 solution enhanced the aggregation propensity of the protein, and
79
remarkably reduced the toxic soluble oligomers, leading to the alleviation of cell
80
damages caused by L-Aβ42 aggregation.9,45 Peptide inhibitors consisting of unnatural
81
D-enantiomers of the amino acids exhibited significantly stronger inhibition potency
82
than their L-enantiomers.25,46 This is considered due to the fact that natural Aβ amino
83
acid residues usually arrange in a specific orientation,43 so D-peptide inhibitors may
84
provide favorable conformations for binding to Aβ. Moreover, D-peptides are
85
resistant to proteolytic degradation and less immunogenic, and have high probability
86
to cross blood-brain barrier (BBB).40,47 All these factors play an dominant role in
87
practical clinical uses of peptide inhibitors. Hence, D-peptide-based inhibitors deserve
88
extensive explorations.
89
However, to the best of our knowledge, there is no research on the influences of
90
chirality of inhibitors on metal-mediated Aβ aggregation as well as on the
91
metal-mediated ROS production. Hence, we have herein reformulated our recently
92
designed bifunctional inhibitor RK10 into its D-enantiomer, rk10. RK10 was designed
93
by adding a chelating tripeptide RTH to LK7’s N-terminus, and showed high
94
specificity towards Cu2+-mediated Aβ aggregation.18 The D-enantiomer, rk10, is
95
expected to display higher inhibition potency, stronger ROS arresting activity on
96
Cu2+-mediated Aβ aggregation and better remodeling effect than its counterpart.
97
Therefore, the differences of the enantiomers in their inhibition performances were
98
extensively investigated by thioflavin T (ThT) fluorescence spectroscopy, dot blot 4
ACS Paragon Plus Environment
Page 4 of 38
Page 5 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
99
assay, atomic force microscopy (AFM), and cell viability assay, and the molecular
100
details about the inhibition mechanisms of the enantiomers were studied by NMR and
101
molecular docking. Then, intrinsic tyrosine (10Tyr) fluorescence quenching assay,
102
7-hydroxycoumarin-3-carboxylic
103
oxidative damage tests and isothermal titration calorimetry (ITC) measurement were
104
performed to assess the chelating property and antioxidant capability of the
105
enantiomers. Thirdly, the effects of the enantiomers on Cu2+-mediated Aβ42
106
aggregation were evaluated by the above biophysical and biological assays. Finally,
107
the remodeling effects of the enantiomers on mature Aβ42/Aβ42-Cu2+ aggregates were
108
explored, and the BBB permeation behaviors of the enantiomers were examined.
109
Results revealed that the chirality effect of the peptide-based inhibitor possesses a
110
critical position in Aβ and Cu2+-mediated Aβ aggregations.
acid
(CCA)
fluorescence,
protein/lipid/DNA
111 112
RESULTS AND DISCUSSION
113
D-Enantiomer Shows Higher Inhibition Efficiency. ThT fluorescence assay was
114
first used to characterize the inhibitory capability of the enantiomeric inhibitors.48
115
Both RK10 and rk10 inhibited Aβ42 aggregation in a concentration-dependent
116
manner, and the D-enantiomer always exhibited stronger inhibition potency than
117
L-enantiomer at the same concentrations (Figure 1A). For example, equimolar RK10
118
reduced the ThT fluorescence intensity to 53%, while its counterpart rk10 suppressed
119
the fluorescence intensity to 27%. At the same time, dot blot assay with OC (Aβ42
120
aggregate-specific) antibody was conducted to differentiate the inhibition efficiency
121
of the enantiomeric inhibitors (Figure 1B). It is seen from the figure that the dot blot
122
assay validated the ThT data. These results are also in good agreement with literature
123
data that the interactions between Aβ and peptide-based inhibitors display a
124
heterochiral stereoselectivity.46
125
D-Aβ42 possesses the ability to accelerate L-Aβ42 fibrillation,9 so it is interesting to
126
investigate the impact of the mirror-image inhibitors on Aβ aggregation kinetics. In
127
situ ThT fluorescence assay and the corresponding normalized lag time (Figure 1C, 5
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
128
1D) revealed that 2.5 μM rk10 (rk10:Aβ40 = 0.1:1) shortened the normalized Aβ40 lag
129
time to 0.80 ± 0.15, and 12.5 μM rk10 (rk10:Aβ40 = 0.5:1) decreased the normalized
130
lag time to 0.64 ± 0.14. So rk10 accelerated the nucleation of Aβ40 at the low
131
concentrations. This phenomenon is similar with the finding that the fibrillogenesis of
132
a racemic mixture of Aβ42 was 3 to 4 times accelerated.9 In contrast, 2.5 and 12.5 μM
133
RK10 increased the lag times to 1.29 ± 0.06 and 1.48 ± 0.22, respectively. Therefore,
134
it can be concluded that RK10 delayed Aβ40 nucleation. The corresponding final ThT
135
fluorescence intensity of Aβ40 incubated with RK10 and rk10 were 86% and 83% at
136
inhibitor:Aβ40 = 0.1:1, and 68% and 21% at inhibitor:Aβ40 = 0.5:1. Similar kinetic test
137
was conducted with Aβ42 (Figure S1 and Table S1), and the acceleration or
138
deceleration phenomenon was also observed at low inhibitor concentrations
139
(especially at 2.5 or 12.5 μM rk10 and at 2.5 μM RK10). The ThT fluorescence
140
indicates that the effects of the chiral inhibitors on Aβ aggregation were distinctly
141
different from each other.
142
Then, the conformational transition of Aβ42 was assessed by circular dichroism
143
(CD) spectroscopy (Figure 1E). Freshly prepared Aβ42 monomer adopted a random
144
coil structure with a negative peak at 200 nm (Figure 1E, black curve). After
145
incubating for 48 h, Aβ42 transformed to β-sheet-rich structures with a negative peak
146
around 216 nm and a positive peak at 195 nm. Equimolar rk10 prevented the
147
conformational transformation from random coil to β-sheet structures. The presence
148
of equimolar RK10 showed a similar structural transition with the sample containing
149
Aβ42 alone. This confirmed the significantly higher inhibitory efficiency of rk10 than
150
RK10 in preventing the conformational transition of Aβ42.
151
Next, we used AFM imaging to observe the morphologies of Aβ40 and Aβ42
152
aggregates co-incubated with the enantiomeric inhibitors. The two enantiomeric
153
inhibitors exhibited little tendency to self-assembling (Figure S2). As illustrated in
154
Figure 1F, Aβ42 alone showed a twisted and elongated fibrillar network with a length
155
of several micrometers. With the increase of RK10 concentration, Aβ42 fibrils became
156
shorter and the amount of fibrils decreased, but there still existed amorphous 6
ACS Paragon Plus Environment
Page 6 of 38
Page 7 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
157
aggregates even at 100 μM. Co-incubating Aβ42 with rk10 showed more remarkable
158
morphological changes and rk10 could alter the pathway of Aβ42 aggregation at lower
159
concentrations. Similar results of Aβ40 incubated with the enantiomeric inhibitors
160
were obtained and illustrated in Figure S3. The results of AFM imaging are in
161
agreement with the above ThT fluorescence assays and CD spectra in the point that
162
Aβ aggregation was more susceptible to the D-enantiomeric peptide inhibitor.
163
Since neuronal toxicity is a natural consequence of Aβ fibrillation, we used
164
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity
165
assay with SH-SY5Y cells to assess the detoxification of the enantiomeric inhibitors.
166
Both RK10 and rk10 showed no significant cytotoxicity within the tested
167
concentration range (Figure S4). As illustrated in Figure 1G, Aβ42 aggregates reduced
168
cell viability to 60% of the control, similar to previous reports.35 RK10 and rk10
169
enhanced cell viability in a dose-dependent manner (Figure 1G). RK10 increased the
170
cell viability to 71% at 25 μM, and 90% at 100 μM. Its enantiomeric counterpart rk10
171
exhibited higher detoxification to Aβ42 species, resulting in 91% at 25 μM and up to
172
97% cell viability at 100 μM. In other words, the detoxification of 25 μM rk10 was
173
equivalent to that of 100 μM RK10, indicating that the inhibitory efficiency of rk10
174
was significantly higher than RK10.
175
From the above results, we could draw the conclusion that rk10 was superior over
176
its L-enantiomer as an inhibitor against Aβ aggregation and cytotoxicity. It is due to
177
its strong suppression on the conformational transition of Aβ to β-sheet-rich structure
178
(Figure 1E), which led to an off-pathway aggregation (Figure 1A, 1B, 1C, 1F) and
179
reduced toxicity of the Aβ species (Figure 1G).
180
The molecular interactions between the enantiomeric decapeptides and Aβ42 were
181
explored by isothermal titration calorimetry (ITC). As shown in Figure S5, the
182
titration data were not able to be fitted by a binding model. This might be due to the
183
complexity of this process including Aβ aggregation and the influence of RK10/rk10
184
on Aβ nucleation. NMR spectroscopy was then used to analyze the binding sites. The
185
1H
NMR signals of Aβ42 changed upon addition of the two enantiomers (Figure 2A); 7
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 8 of 38
186
the amide protons of E22 (Figure 2B) and aromatic moieties of F19F20 (Figure 2C)
187
underwent remarkable changes, indicating the enantiomers interacted with these sites.
188
To further understand and visualize the interactions of the decapeptides with Aβ
189
monomers, docking studies were performed with monomeric Aβ40 (PDB ID 2LFM)
190
and Aβ42 (PDB ID 1IYT). As shown in Figures 3A and S6A, rk10 binds to the
191
hydrophobic region of Aβ40 (binding energy, -6.0 kcal/mol) through polar and
192
nonpolar interactions, but RK10 presents weaker binding energy with Aβ40 (-5.4
193
kcal/mol) (Figure S6A). Similar results were obtained in the molecular docking with
194
Aβ42 monomer (Figure 3B, 3C and Figure S6B); rk10 had higher binding energy (-4.5
195
kcal/mol) to Aβ42 than RK10 (-3.1 kcal/mol). The predicted conformations supported
196
the NMR data that the decapeptides bound to the hydrophobic region of the amyloid
197
protein. This result also confirmed the hypothesis that a D-enantiomer might provide
198
favorable conformations for binding to Aβ.45 Therefore, the D-enantiomer exhibited
199
higher inhibition efficiency than its enantiomeric counterpart.
200
Chelating Property of the Enantiomers and Protection from the Damage of
201
ROS. Aβ42 interacts with Cu2+ and leads to the extinction of
202
fluorescence, so
203
property of the enantiomers.49 The 10Tyr fluorescence intensity reduced to 54% upon
204
addition of 10 µM Cu2+, RTH/rth and RK10/rk10 restored the 10Tyr fluorescence in a
205
concentration-dependent manner (Figure 4A). On the other hand, the tested peptides
206
had no significant influence on the
207
the 1H NMR signals at the aromatic moiety of Tyr centered at 6.8 ppm changed up the
208
interactions as shown in Figure 2C, indicating that RK10/rk10 interacted with this
209
site. The above results signify that RTH, rth, RK10, rk10 sequestered Cu2+ from the
210
Aβ42-Cu2+ complexes and the two enantiomers had a similar behavior towards Cu2+
211
chelation and sequestration. This result is consistent with the conclusion that D- and
212
L-Aβ42 are chemically equivalent with respect to copper binding.45
10Tyr
10Tyr
intrinsic
fluorescence assays were performed to assess chelating
10Tyr
fluorescence of Aβ42 (Figure S7), although
213
Then, toxic ROS production catalyzed by Cu2+ was measured by CCA fluorescence
214
assays. The tripeptides RTH and rth showed similar abilities to suppress ROS 8
ACS Paragon Plus Environment
Page 9 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
215
generation (Figure S8). Rationally, RK10 and rk10 retained the metal chelation
216
property of the tripeptides and completely quenched the production of HO• at high
217
concentrations (Figure 4B). At the same time, the consumption of Asc validated the
218
CCA fluorescence results (Figure S9). These results confirmed the antioxidant
219
property of the enantiomeric decapeptides. In the presence of Aβ42, although Aβ42
220
suppressed the final Cu2+-Asc fluorescence (ROS level) to 16% (Figure 4C), Aβ42
221
itself could not quench the Fenton-type reactions because Aβ42 contains various amino
222
acids (e.g., 35Met) that possess complex redox properties.13 Further addition of RK10
223
or rk10 to the sample completely eradicated the ROS generation (Figure 4C),
224
indicating that RK10 and rk10 interacted with Aβ42-Cu2+ complex and stopped the
225
redox cycle.
226
The overproduction of ROS could cause oxidative damage of biomolecules such as
227
protein, lipids and DNA, and further trigger neuronal death, which is vital in the
228
pathology of AD.11 Therefore, the multifaceted protection effects of the enantiomeric
229
decapeptides were explored. Protein oxidation can lead to protein fragmentation and
230
cross-linking. The percentage of protein oxidation was detected and illustrated in
231
Figure 4D. RK10 significantly reduced protein oxidation to 59% at 50 μM
232
(Cu2+:RK10=1:0.5) and to 36% at 100 μM (Cu2+:RK10=1:1). Similar data were
233
obtained for rk10. So the enantiomeric decapeptides protect protein from oxidation.
234
ROS-induced lipid peroxidation is an important mechanism of neurodegeneration
235
in AD brain. The lipid peroxidation was measured by the TBARS assay. In the
236
presence of Cu2+, MDA was detected by UV spectrometer at 532 nm, implying that
237
phospholipid was damaged by ROS. From Figure 4E, co-incubating the enantiomeric
238
decapeptides decreased phospholipid peroxidation to 60%~68% at 100 μM
239
(Cu2+:Peptide=1:1), and to 11%~21% at 200 μM (Cu2+:Peptide=1:2). This indicates
240
the effective anti-oxidation of the enantiomeric multifunctional decapeptides.
241
Oxidation of nuclear and mitochondrial DNA have also been reported in AD. Thus,
242
in vitro experiment was designed to validate the DNA protection effect of RK10/rk10.
243
Plasmid DNA (pDNA) was treated with Cu2+-Asc and then analyzed by agarose gel 9
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
244
electrophoresis (Figure 4F). There existed supercoiled and relaxed forms in pDNA in
245
the absence of Cu2+-Asc, but the supercoiled form pDNA disappeared in the presence
246
of Cu2+-Asc, indicating that pDNA was damaged by ROS. Interestingly, the
247
enantiomeric decapeptides prevented pDNA from the damage of ROS.
248
In summary, the above in vitro anti-oxidative results indicate that RK10 and rk10
249
rescued protein, lipids and DNA from the oxidative damage of ROS, and their
250
protecting effects were similar.
251
Thus, the
10Tyr
fluorescence assay, CCA fluorescence measurement and
252
anti-oxidative experiments suggest that RK10 and rk10 retained the chelation property
253
of the tripeptides (RTH/rth), and the effects of the enantiopure counterparts on
254
stripping Cu2+ from Aβ42-Cu2+ species and suppressing the ROS generation were
255
similar. To further understand the interactions between the enantiomers and Cu2+, ITC
256
measurements were performed. The ITC data indicate that there was no significant
257
difference between the enantiomeric decapeptides on their binding affinities for Cu2+
258
(Figure S10, Table 1). The binding constant of Aβ to Cu2+ has been reported to be
259
0.974×106 M-1.13 Therefore, it would be strong enough for RK10/rk10 to isolate or
260
strip Cu2+ from Aβ42-Cu2+ complex because of their one order of magnitude higher
261
binding affinities. Notably, RK10/rk10 might not be able to sequester Cu2+ from
262
Cu-metalloproteins, because their binding affinities (3.2-3.6×107 M-1, Table 1) were
263
lower than Cu-metalloproteins (such as Cu-Zn superoxide dismutase (~1012 M-1)).
264
Therefore, the moderate affinity of RK10/rk10-Cu2+ might make it a good chelator for
265
AD treatment without interfering with the normal biological functions of Cu2+.
266
Enhanced Inhibition of Cu2+-Mediated Aggregation by the D-enantiomer. It
267
has been recognized that Cu2+ can accelerate the conformational transition of Aβ
268
monomers and facilitate the generation of more toxic aggregates.19 In this section, we
269
investigated the effects of the enantiomeric decapeptides on Cu2+-mediated Aβ42
270
aggregation (Figure 5). Cu2+ induced Aβ42 to aggregate into less β-sheet structures,
271
and the ThT fluorescence of Aβ42-Cu2+ aggregates decreased to 18% (Figure 5A).
272
Addition of the tripeptides gradually restored the ThT fluorescence to 100%, so the 10
ACS Paragon Plus Environment
Page 10 of 38
Page 11 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
273
tripeptides inhibited Cu2+-induced Aβ42 aggregation by chelating Cu2+. However, the
274
tripeptides were incapable of inhibiting Aβ42 aggregation. In contrast, RK10 and rk10
275
kept the ThT fluorescence intensity around 11% to 19%, demonstrating the
276
enantiomeric decapeptides inhibited not only Cu2+-induced Aβ42 aggregation by
277
chelating Cu2+, but also the self-aggregation of Aβ42 after stripping the copper ions
278
from the Aβ42-Cu2+ complexes.
279
Cu2+-mediated Aβ42 aggregation led to the formation of amorphous aggregates
280
(Figure 5B), which was in line with previous reports.19 RK10 gradually changed the
281
morphology of Cu2+-Aβ42 aggregates from amorphous to fibrillar structures.
282
Meanwhile, neither amorphous nor fibrillar structured aggregates were observed in
283
the presence of 100 μM rk10. This result is considered due to the different inhibition
284
efficiency of the enantiomeric decapeptides after isolating Cu2+ from the Aβ-Cu2+
285
complexes, as demonstrated in Figure 1F. The results of AFM imaging suggest that
286
the D-enantiomer possesses stronger inhibition efficiency on Cu2+-mediated Aβ42
287
aggregation than its L-enantiomeric counterpart as do in the inhibition of Aβ42
288
aggregation (Figure 1A, 1F).
289
Moreover, the detoxification of the enantiomers on Aβ42-Cu2+ aggregates were
290
assessed by the MTT assay. Aβ42 aggregates into more toxic species induced by Cu2+.
291
The viability of SH-SY5Y cells reduced to 51%, and the enantiomeric tripeptide
292
RTH/rth failed to provide protection to the cells against Aβ42-Cu2+ toxicity (Figure
293
5C). RK10 enhanced the cell viability to 68%, 74%, and 83% at the molar ratios of
294
RK10:Aβ42 at 1, 2 and 4, respectively. Interestingly, the rk10 showed significantly
295
higher detoxification than RK10; it rescued the cell viability to 74%, 89%, and 91% at
296
rk10: Aβ42 at 1, 2 and 4, respectively. Remarkably, the biological effect of 50 μM
297
rk10 was more significant than 100 μM RK10 on alleviating Cu2+-mediated Aβ
298
cytotoxicity. The detoxification study further confirmed the advantage of the
299
D-enantiomer over its L-enantiomeric counterpart on Cu2+-mediated Aβ42
300
aggregation.
301
Excessive ROS formations from the redox of Aβ42-Cu2+ aggregation and the 11
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 12 of 38
302
self-aggregation
303
2′,7′-dichlorofluorescin diacetate (DCFH-DA) was then used as a fluorescence probe
304
to study the intracellular oxidant stress.17,19 As illustrated in Figure 6, SH-SY5Y cells
305
treated with Aβ42 aggregates showed 167% ROS generation, and Cu2+ dramatically
306
promoted the ROS production to 216%. The ROS generation data are similar with
307
those reported in literature.19 Intriguingly, equimolar RK10 decreased the ROS
308
production caused by Aβ42-Cu2+ species to 148%, and equimolar rk10 attenuated ROS
309
level to 114%. This result was in good agreement with the MTT assays (Figure 5C)
310
and confirmed the efficient antioxidant property of rk10 in vivo. Considering the
311
higher inhibition potency of rk10 than RK10 on Aβ aggregation, the excellent
312
antioxidant and detoxification characteristics in cellular level might be due to its
313
enhanced interactions with Aβ in the presence of Cu2+. In other words, although rk10
314
possesses similar chelation property with RK10, it could suppress more ROS
315
generated by Aβ aggregation than RK10, so the cytotoxicity induced by Aβ42-Cu2+
316
was more significantly alleviated by rk10.
of
Aβ42
cause
mitochondrial
damage
and
cell
death.17
317
Remodeling Mature Aβ42-Cu2+ Aggregates and Preventing Reaggregation. The
318
removal of existing amyloid plaques is another therapeutic target in AD treatment and
319
this property is considered as the merit of a potential therapeutic agent,19,50 so the
320
influences of the enantiomeric inhibitors on mature Aβ42 species (25 μM) were
321
assessed. On the Aβ42 fibrils formed in the absence of Cu2+ ions, the final ThT
322
fluorescence intensity showed no significant decrease and the morphology of Aβ42
323
fibrils remained unchanged (Figures S11 and S12), implying that the inhibitors were
324
unable to disrupt mature Aβ42 aggregates. This result is in accordance with our
325
previous work dealing with bifunctional agents with a metal-chelating capability.19
326
Then, the effects of the enantiomeric inhibitors on aged Aβ42-Cu2+ aggregates were
327
investigated. As mentioned above in the discussion on the results shown in Figure 4B,
328
Aβ42-Cu2+ aggregates displayed amorphous structures. After co-incubating the
329
Aβ42-Cu2+ aggregates with the enantiomeric tripeptide RTH/rth, the morphology of
330
Aβ42-Cu2+ species transformed into mixed fibrillar and amorphous structures (Figure 12
ACS Paragon Plus Environment
Page 13 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
331
S13), which indicates that the chelator disaggregated the mature Aβ42-Cu2+ aggregates
332
in part or all by chelation, and the disaggregated species remodeled into fibrils in part
333
in the absence of Cu2+ ions, as previously reported.50 The decapeptides also exhibited
334
the ability to modulate mature Aβ42-Cu2+ species (Figure 7A). By treating Aβ42-Cu2+
335
species with RK10, the morphology of the aggregates transformed into fibrils, plaques
336
and less visible amorphous structures at high concentrations (Figures 7A and S14).
337
Addition of rk10 to Aβ42-Cu2+ aggregates changed the morphology from amorphous
338
to twisted fibril structures at 25 μM, and only very small amount of amorphous
339
aggregates could be observed at 50 and 100 μM rk10. More importantly, it has been
340
reported that the disaggregated Aβ42-Cu2+ could reaggregate to β-sheet-rich structures
341
and toxic forms,50 implying the inhibiting potency of an inhibitor plays a dominant
342
role in the later period of disaggregation. Therefore, in situ ThT fluorescent assays
343
were conducted to analyze the process of disaggregation and reaggregation. The
344
fluorescent intensity of the RTH/rth-treated Aβ42-Cu2+ aggregates increased in the
345
following co-incubation (Figure S15), demonstrating that removal of Cu2+ from
346
Aβ42-Cu2+ species led to the formation of β-sheet-rich structures. With 12.5 μM
347
RK10, the ThT fluorescence intensity dropped slightly in the first 3 h, and gradually
348
recovered to the control (Aβ42-Cu2+ aggregates) level (Figure 7B, line 2). This result
349
implies that RK10 could disaggregate Aβ42-Cu2+ aggregates, but a low concentration
350
of RK10 was incapable of preventing reaggregation of the disrupted aggregates due to
351
its moderate inhibition efficiency. By contrast, no obvious increase of fluorescence
352
intensity was observed in the samples treated by the D-enantiomer at the same
353
concentration. This evidently indicates the stronger inhibitory effect of rk10 than
354
RK10 in suppressing the reaggregation of the disaggregated species after removal of
355
Cu2+ from Aβ42-Cu2+ species.
356
The remodeling effect of the enantiomers on mature aggregates was further
357
confirmed by MTT assays (Figure 7C). Mature Aβ42 aggregates reduced the cell
358
viability to 70% of control, and the effects of RK10 and rk10 on the cytotoxicity of
359
the mature Aβ42 aggregates were negligible. This result is consistent with ThT assays 13
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
360
(Figure S11) and AFM imaging (Figure S12). In contrast, Aβ42-Cu2+ aggregates
361
reduced the cell viability to 57%, and equimolar RK10 and rk10 treated Aβ42-Cu2+
362
aggregates increased cell viability to 86% and 96%, respectively. Cell viability assays
363
indicate that both the enantiomeric inhibitors were capable of dissociating preformed
364
Aβ42-Cu2+ aggregates and alleviating the toxicity of the aggregates. Similarly with the
365
above results about inhibition of aggregation and ROS production, the D-enantiomer
366
showed higher potency on remodeling mature Aβ42-Cu2+ species than its
367
L-enantiomeric counterpart.
368
Taken together, the above results indicate that the D-enantiomeric decapeptide rk10
369
possessed higher inhibition efficiency on Aβ aggregation than its L-counterpart. To
370
achieve a similar effect on rescuing SH-SY5Y cells, the effective concentration of
371
rk10 was only 1/4 of RK10 (Figure 1G). In the presence of Cu2+, the D-enantiomer
372
exhibited higher suppression to Cu2+-mediated Aβ aggregation, and protected cultured
373
cells from Cu2+-mediated Aβ cytotoxicity at lower concentrations than RK10 (Figure
374
5C). Intercellular test revealed that rk10 suppressed more ROS generated by Aβ
375
aggregation as well as Cu2+-mediated Aβ42 aggregation than RK10 (Figure 6).
376
Moreover, rk10 showed higher performance in remodeling mature Aβ42-Cu2+
377
aggregates by Cu2+ chelation, and higher ability on protecting the disrupted species
378
from reaggregation (Figure 7). By contrast, the enantiomers showed similar
379
anti-oxidative effects on rescuing protein, lipids, and DNA from the oxidative damage
380
of ROS (Figure 4). Therefore, the superiority of D-enantiomer over L-enantiomer was
381
on its enhanced inhibition towards Aβ aggregation, Cu2+-mediated Aβ aggregation,
382
intracellular ROS, as well as remodeling effects.
383
Finally, passive BBB permeability of the enantiomeric decapeptides were evaluated
384
by parallel artificial membrane permeation assay (PAMPA).51 According to the
385
criteria established by Di et al,51 under our experimental condition, samples with
386
permeability (P) values greater than 3.8×10-6 cm/s are regarded to be able to cross the
387
BBB, while those less than 1.7×10-6 cm/s exhibit low BBB permeation (Table S2,
388
Figure S16, Table S3). The P values of RK10 and rk10 were determined to be 14
ACS Paragon Plus Environment
Page 14 of 38
Page 15 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
389
1.16×10-6 and 1.24×10-6 cm/s, respectively (Table S4). This indicates that the
390
enantiomeric decapeptides were of poor BBB permeation with the PAMPA-BBB
391
model. To enhance the BBB permeability of the inhibitors, one way that can be
392
considered is to conjugate the peptide to a cell-penetration peptide (CPP) or to
393
nanoparticles coupling with such a CPP.52
394 395
CONCLUSIONS
396
In this work, a D-enantiomeric decapeptide, RTHLVFFARK-NH2, was
397
systematically investigated for its effect on Aβ and Cu2+-mediated Aβ aggregations by
398
comparison with its L-enantiomeric counterpart. Both the enantiomers possess
399
multifunctionality in inhibiting Cu2+-mediated Aβ aggregation, arresting ROS
400
production, remodeling mature Aβ-Cu2+ aggregates and attenuating related
401
cytotoxicity, but the D-enantiomer is obviously superior over the L-enantiomer in the
402
following aspects. (1) The D-enantiomer shows significantly higher inhibition
403
efficiency on Aβ aggregation. (2) The enantiomers are chemically equivalent with
404
respect to copper binding, ROS suppression, and oxidative damage rescue, but the
405
D-enantiomer exhibits more excellent ability on inhibiting Cu2+-mediated Aβ
406
aggregation, alleviating the corresponding cytotoxicity, and attenuating ROS damage
407
generated by Aβ42 and Aβ42-Cu2+ aggregates. (3) Both the enantiomeric decapeptides
408
could remodel mature Aβ-Cu2+ species as high affinity Cu2+ chelators, but it was the
409
D-enantiomer that could protect the disrupted aggregates from reaggregation and
410
showed higher detoxification on the Aβ-Cu2+ complexes. The findings would help
411
design of more potent multifunctional peptide inhibitors.
412 413
METHODS
414
Materials. Synthetic Aβ42, Aβ40 were purchased from GL Biochem (Shanghai,
415
China). Decapeptide RK10/rk10 and tripeptide RTH/rth were all obtained with a
416
purity of >95% from ZiYu Biotechnology (Shanghai, China. The LC-MS
417
characterization data are shown in Figure S16 and Figure S17). The C-terminus of the 15
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 16 of 38
418
decapeptide was amidated. 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), ThT, MTT,
419
BSA, HEPES were purchased from Sigma-Aldrich (St. Louis, MO, USA).
420
Coumarin-3-carboxylic acid (CCA), L-ascorbic acid (Asc) were received from J&K
421
Scientific Ltd. Porcine brain lipid was purchased from Avanti Polar Lipids.
422
Dulbecco’s modified Eagle’s medium /Ham's Nutrient Mixture F-12 (DMEM/F12)
423
and fetal bovine serum (FBS) were obtained from Gibco Invitrogen (Grand Island,
424
NY, USA). Human neuroblastoma SH-SY5Y cells were received from the Cell Bank
425
of the Chinese Academy of Sciences (Shanghai, China). Anti-amyloid fibrils OC
426
antibody
427
chemiluminescence kit were received from Beyotime, China. Nitrocellulose
428
membranes were purchased from PALL Gelman Laboratory. All other chemicals
429
including metal chloride salts were analytical reagent grade and used without further
430
purification.
was
obtained
from
Merck
Millipore.
DCFH-DA
and
ECL
431
Thioflavin T (ThT) Binding Fluorescence. The measurement of ThT fluorescence
432
intensity was used to quantitatively assess cross-β structures.48 Briefly, 200 μL sample
433
was mixed with 2 mL ThT solution (25 μM in HEPES buffer). The excitation and
434
emission wavelengths were 440 and 480 nm, respectively. The fluorescence intensity
435
of inhibitor and buffer was subtracted as background, final data were normalized with
436
Aβ only samples.
437
We used in situ ThT assay to monitor Aβ40/Aβ42 aggregation kinetics with or
438
without decapeptides. A volume of 200 μL samples containing 25 μM Aβ40/Aβ42
439
monomers, 25 μM ThT and different concentration of the enantiomeric decapeptides
440
were added into 96-well plate. The aggregation kinetics was measured using a
441
fluorescence plate reader (TECAN Austria GmbH, Grödig, Austria) at 10 min reading
442
intervals and 5 s shaking before each read. Data for Aβ40 were averaged from six
443
replicates and fitted by the sigmoidal Boltzmann model Eq.(1), and the lag time (Tlag)
444
was calculated from Eq. (2).
445
ymax - y0
y = y0 + 1 + exp( -k(t - t1/2))
16
ACS Paragon Plus Environment
(1)
Page 17 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
2
446
Tlag = t1/2-
k
(2)
447
where y, y0, ymax, k, t1/2 represent fluorescence intensity at t, minimum fluorescence
448
intensity, maximum fluorescence intensity, apparent first-order aggregation constant,
449
the time required to reach half the maximum fluorescence intensity, respectively. Data
450
for Aβ42 were averaged from six replicates and the lag time is defined as the time
451
required to reach half the maximum of fluorescence intensity.
452
Dot Blot Assay. In the assay, 20 μL aliquots of peptide-treated Aβ42 samples were
453
spotted on nitrocellulose membranes, and the membranes were blocked with 10%
454
skimmed milk in 20 mM Tris-buffered saline (pH 7.4) with 0.01% Tween 20 (TBS-T)
455
for 1 h at room temperature. Then, the membranes were washed three times with
456
TBS-T. The membranes were incubated with the primary antibody OC (1:3000) (Aβ42
457
aggregates-specific antibody) for 1h at room temperature. After rinsing with TBS-T,
458
the membranes were incubated with the secondary antibody (anti-rabbit IgG, 1:
459
40000) conjugated with horseradish peroxidase for another 1h, and detected using
460
ECL chemiluminescence kit.
461
Circular Dichroism (CD) Spectroscopy Measurements. CD spectra were
462
collected with a JASCO J-810 spectrometer using a 1 mm path length quartz cell at
463
37 °C. The parameters were controlled as 1 nm bandwidth, and 100 nm/min scanning
464
speed with a continuous scanning model. Data were averaged from there independent
465
samples.
466
Atomic Force Microscopy (AFM) Imaging. AFM was used to monitor the
467
morphologies of Aβ species. After the protein aggregated, aliquots of 50 μL of each
468
sample were placed on a freshly cleaved mica substrate. After incubation for 5 min,
469
the substrate was rinsed with 8 mL DI water and dried by N2 stream before
470
measurement. Images were acquired in the tapping mode on an atomic force
471
microscope (Primitive Nano Inc., Guangzhou, China) under ambient conditions.
472
MTT Cell Viability Assay. The human neuroblastoma SH-SY5Y cells were
473
cultured in DMEM/F12 medium with 10% FBS, and 1% penicillin-streptomycin
474
antibiotic (100 U/mL penicillin and 100 μg/mL streptomycin sulfate) at 37 °C in an 17
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
475
atmosphere of 5% CO2. For MTT cell viability assays, the cells were seeded for 24 h
476
in a 96-well plate at density of 8×103 cells/well. Then different kinds of testing
477
samples that have been pre-incubated for 18 h were introduced to the cells and treated
478
for additional 24 h. The final concentration of Aβ42 in the cells was 5 μM. After that,
479
10 μL of MTT solution (5.5 mg/mL in HEPES buffer) was added into each well and
480
incubated for another 4 h. Afterwards, the plate was centrifuged at 1500 rpm for 10
481
min to discard the medium and 100 μL DMSO was added to lyse cells. Finally, the
482
absorbance at 570 nm was measured by a multimode microplate reader (TECAN
483
Austria GmbH, Grödig, Austria). Data were obtained from the average of six
484
replicates in this part.
485
Isothermal Titration Calorimetry (ITC). ITC measurements were performed on
486
a VP-ITC microcalorimeter (MicroCal, Northampton, MA) at 37 °C to detect the
487
binding affinities of the enantiomeric inhibitors with Aβ42 and Cu2+. For minimized
488
perturbations caused by air bubbles, all samples needed to be degassed by
489
centrifugation at 6000 rpm, 30 °C for 10 min before titration. Measurements were
490
conducted in 20 mM HEPES buffer (100 mM NaCl, pH = 7.4). Stirrer speed was kept
491
at 307 rpm. Each injection was 10 μL. To detect the binding of the inhibitors to Aβ42,
492
an RK10/rk10 solution at 200 μM was injected into a cell containing 20 μM Aβ42
493
monomer to achieve a complete binding isotherm. Similar experiment was conducted
494
with 2.5 mM copper chloride to 0.5 mM RK10/rk10 (10 mM glycine was contained in
495
the HEPES buffer for stabilizing Cu2+).13,18 The resulting dilution were determined
496
and subtracted from the integrated data before curve fitting. The data were fitted and
497
analyzed by one-site binding model of the MicroCal version of ORIGIN 7.0 software
498
to obtain ΔH, TΔS and association constant (K).
499
NMR Spectroscopy. 1H NMR experiments were carried out in 10 mM Tris buffer
500
containing 150 mM NaCl (pH 7.4) with 10% D2O. Samples containing 0.1 mM Aβ42
501
were mixed with the enantiomeric decapeptides (0.2 mM). NMR data were
502
immediately acquired on a Bruker 600 MHz spectrometer.
503
Molecular Docking. Molecular docking was accomplished using AutoDock Vina 18
ACS Paragon Plus Environment
Page 18 of 38
Page 19 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
504
(http://vina.scripps.edu).53,54 The three-dimensional crystal structures of Aβ40 and
505
Aβ42 monomers were retrieved from protein data bank (PDB ID 2LFM and 1IYT,
506
https://www.rcsb.org).55,56 Using AutoDock Vina, binding calculations were made
507
between receptor Aβ monomer and the enantiomeric decapeptides. RK10/rk10 was
508
chosen as the flexible ligand and Aβ monomer was fixed. The Lamarckian Genetic
509
Algorithm was used for the calculations. All other parameters were set as default. The
510
docking poses were captured using VMD tools.
511
Tyrosine Fluorescence Spectroscopy Assay. The intrinsic fluorescence of 10Tyr at
512
Aβ42 can be quenched by binding with Cu2+. Chelators can sequester Cu2+ from
513
Aβ42-Cu2+ complex, resulting in fluorescence recovered. Tyrosine fluorescence were
514
measured to assess the effects of chelating agents on Aβ42 /Aβ42- Cu2+ complex.23
515
Aβ42 (25 μM) with or without Cu2+ (10 μM) were incubated with different kinds of
516
chelating agents for 20 min at 37 °C. Tyrosine fluorescence intensity were measured
517
by
518
excitation/emission of 274/299 nm, respectively.
fluorescence
spectrometer
(PerkinElmer,
LS-55,
MA,
USA)
at
an
519
Measurement of HO• in vitro. Hydroxyl radical is one of the unstable
520
intermediates generated by Fenton-type reactions. The production of hydroxyl radical
521
was measured with coumarin-3-carboxylic acid (3-CCA) as the fluorescent probe.
522
3-CCA could be oxidized to 7-hydroxycoumarin-3-carboxylic acid (7-OH-CCA) by
523
HO•. Thus the time-dependent production of HO• was measured by monitoring
524
7-OH-CCA fluorescent signal at 452 nm upon excitation at 395 nm (slit width = 5.0
525
nm). The concentration of 3-CCA, Cu2+, Asc, Aβ42 were 500 μM, 10 μM, 500 μM, 25
526
μM, respectively for all measurements. Asc should be added into the testing sample at
527
last before experiments.
528
Ultraviolet Measurement of Ascorbic Acid. The samples for UV test consist of
529
10 μM Cu2+, 500 μM Asc and different concentration of chelating agents. A volume
530
of 1 mL testing sample was injected into quartz pool with l=0.5 cm. The consumption
531
of Asc was recorded by an ultraviolet spectrometer at 265 nm.
532
Multifaceted Anti-Oxidation Assays. Protein oxidative damage was measured by 19
ACS Paragon Plus Environment
ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
533
co-incubating bovine serum albumin (BSA) with 2,4-dinitrophenylhydrazine
534
(DNPH).17 Lipid peroxidation was assessed by the TBARS test.57 DNA damage was
535
detected by agarose electrophoresis.17 Detailed experimental methods are provided in
536
the Supporting Information.
537
Measuring Intracellular ROS Levels. The effects of the enantiomeric
538
decapeptides on Aβ42-Cu2+ complex induced oxidative stress was performed with
539
SH-SY5Y cells by DCFH-DA fluorescence assay.19 According to manufacturer’s
540
protocol, SH-SY5Y cells were seeded in a 96-well plate at a density of 8×103
541
cells/well, Aβ42 samples were added after 24 h, and co-incubated for 24 h. Then, the
542
cells were washed with HEPES buffer twice and incubated with FBS-free medium
543
containing 10 μM DCFH-DA for 30 min at 37 °C. The cells were washed twice and
544
fluorescence intensity at 535 nm was recorded with excitation wavelength at 488 nm
545
using microplate reader.
546 547
In Vitro BBB Permeation Assay. This section is available in the Supporting Information.
548
Data Analysis. Data are shown as mean ± standard deviation. One-way ANOVA
549
with Tukey’s post hoc test was employed to assess the statistically significant, and p